e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Cutting edge: drug delivery to the airways
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Mesoporous silica-based nanoparticles for targeted delivery of proteasome inhibitors to the lung
S. H. van Rijt, C. Argyo, D. A. Bölükbas, O. Eickelberg, T. Bein, S. Meiners (Munich, Germany)
Source:
Annual Congress 2013 –Cutting edge: drug delivery to the airways
Session:
Cutting edge: drug delivery to the airways
Session type:
Oral Presentation
Number:
221
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S. H. van Rijt, C. Argyo, D. A. Bölükbas, O. Eickelberg, T. Bein, S. Meiners (Munich, Germany). Mesoporous silica-based nanoparticles for targeted delivery of proteasome inhibitors to the lung. Eur Respir J 2013; 42: Suppl. 57, 221
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Related content which might interest you:
Combinatorial delivery of targeted mesoporous silica nanoparticles for lung cancer therapy
Source: International Congress 2016 – Basic science and case reports in lung cancer
Year: 2016
MMP-9 responsive mesoporous silica nanoparticles for local drug delivery to NSCLC cells
Source: International Congress 2014 – Thoracic tumours: news from the lab
Year: 2014
Encapsulation of vinorelbine in polymeric nanoparticles improves efficacy in cancer cells and reduces inflammation in non-cancer cells
Source: International Congress 2016 – Late-breaking translational research in lung cancer
Year: 2016
Metabolic modification as a potential therapeutics approach in lung cancer
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Effect of avidin protein coated and uncoated mesoporous silica drug nanocarriers on their bioresponse in the lung
Source: International Congress 2014 – Novel epigenetic regulators for targeting via nanomedicine
Year: 2014
Development of a novel nano-sized carrier system for aeroseol drug delivery (EGE University translational pulmonology research group)
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015
Exploiting metabolomic approaches to aid in the diagnosis of lung cancer
Source: International Congress 2016 – Prognostic variables in lung cancer II
Year: 2016
Use of decellularized tracheas for airways engineering
Source: International Congress 2016 – Current challenges in thoracic surgery
Year: 2016
Effect of 17-oxo-DHA alone and in combination with gemcitabine on lung cancer cell growth
Source: International Congress 2016 – Late-breaking translational research in lung cancer
Year: 2016
Gene therapy with DDMC-p53 with or without cisplatin and microwave ablation. A future concept for local treatment in lung cancer
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Metronomic chemotherapy in human lung cancer: Mathematical modeling for an optimal schedule
Source: International Congress 2015 – Lung cancer therapy: clinical trials
Year: 2015
Antitumor efficacy of the double suicide genesin lung cancer cells
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Development of a lung slice methodology to study the mechanisms of lung uptake and lysosomal trapping
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
The research on early detection of lung cancer with exhaled volatile organic compounds
Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours
Year: 2014
Cetuximab administered through pulmonary route in a mice model of lung tumor
Source: Annual Congress 2013 –Advances in the therapy of lung cancer
Year: 2013
CK2 enzyme affinity against c-myc
424-434
substrate in human lung cancer tissue
Source: Annual Congress 2013 –Genetics and genomics of lung disease
Year: 2013
Integrative analysis of DNA copy number in metastatic NSCLC identifies drug sensitivity to Afatinib
Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Year: 2014
Cox-2 inhibitors in the treatment of small cell lung cancer patients
Source: International Congress 2015 – Advances in the therapy of lung cancer
Year: 2015
A polypeptide of the megakaryocyte potentiating factor is a potential biomarker in plasma for the detection of mesothelioma
Source: International Congress 2016 – Human responses to exposure, including physiological and biomarker outcomes
Year: 2016
Comprehensive evaluation of nuclear factor-κΒ expression patterns in non-small cell lung cancer
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept